Only One of These Drugs Is Approved for Your Teenager

The question underneath the question

A mother who has spent a year reading about these drugs for herself arrives at a different question eventually, usually late and usually alone: what about my kid?

She is not unusual for having it. In a 2026 survey of 211 parents who had been prescribed obesity medications themselves — 80% of them mothers — half had talked with their child about the decision to take them, and three-quarters of those talked about it openly⁴. Whatever else is happening in these households, the subject is not staying quiet.

The answer is narrower than the conversation around it suggests, and it is worth having precisely because the internet will hand you four brand names as though they were four options.

The approval map

One product. Not one molecule, not one company — one formulation. Semaglutide taken as a weekly injection is approved from age 12. The same molecule as a daily tablet is not¹.

That catches people out, and it is the most useful line on this page. If your teenager has said she would consider a pill but not a needle, the pill is the version nobody has established in someone her age.

What the trial actually measured

The pediatric approval rests on one study — 68 weeks, double-blind and placebo-controlled, in 201 pubertal patients aged 12 and older whose BMI sat at or above the 95th percentile for their age and sex¹. The mean age was 15. Sixty-two percent were girls. Everyone did a 12-week lifestyle run-in first, then was randomized two-to-one to the drug or to placebo.

Read the placebo column first. Those teenagers did not hold steady — their BMI drifted up and their body weight rose nearly 3%, on a lifestyle program, under trial conditions¹. That is the honest shape of adolescence: the comparison group is not a body standing still, it is a body still growing. It is also why the difference from placebo, −16.7 percentage points, is larger than the drug group's own −16.1%.

Two caveats the label supplies itself. The primary endpoint was percent change in BMI, not body weight — the standard in pediatrics, because raw pounds mean something different in a fifteen-year-old. And the body-weight row and the responder rates were not part of the pre-specified statistical testing¹, which makes them descriptive rather than proven. The discontinuation figure is worth a second look too: 10% in both arms.

What is different in a teenager

Adverse reactions in adolescents were "generally similar" to adults, with named exceptions. Compared with adults on the same drug, pediatric patients aged 12 and older had greater incidences of cholelithiasis, cholecystitis, hypotension, rash and urticaria¹ — gallstones, gallbladder inflammation, low blood pressure, and two skin reactions.

Gallstones tracking with rapid weight loss is a known feature of this class in adults too. Seeing it more in the younger group belongs in a first conversation rather than a fourth.

There is also an explicit gap. For adolescents who also have type 2 diabetes, the label states there are insufficient data to know whether the risk of hypoglycemia is higher than in adults, and instructs that blood glucose be monitored before and during treatment¹. "We do not know yet, so measure it" is a reasonable instruction. It is not reassurance.

What the teenagers themselves said

The most useful research here is not a trial. In 2026, researchers interviewed 29 adolescents and young adults aged 12 to 22 who were taking or considering these medications, along with 23 of their caregivers — 22 mothers and one grandmother⁵.

One finding should be read twice by anyone about to have this conversation. The young people emphasized weight loss. The caregivers emphasized health. Same decision, same room, two different objectives — and neither side necessarily says so out loud.

The rest is textured in ways a label cannot be. High appetite was a main reason for starting, and the medications reduced appetite and food noise. Binge eating was reported by participants before treatment. Well-being improved, and at the same time stigma about taking the medication was a live concern for them. Parents turned out to be the practical and emotional infrastructure of the whole thing. And nobody — young people or caregivers — felt settled about when or whether to stop⁵.

The authors' own conclusion is worth carrying: this needs shared decision-making built on caregiver support, and future research should look for disordered eating in this population⁵. That last clause is a researcher's way of saying the screening is not routine yet.

The question the 68 weeks cannot answer

Sixty-eight weeks is a long study and a short adolescence.

A 2026 perspective piece in Childhood Obesity names the concern most directly: adolescence is when muscle and bone mass are laid down fastest, and weight loss during that window may attenuate that accrual, potentially lowering peak musculoskeletal capacity and raising frailty risk much later⁶. It is a perspective rather than a finding — the longitudinal pediatric data does not exist — and its recommendation is practical rather than cautionary: pair the medication with resistance training, weight-bearing activity and deliberate nutrition rather than treating it as a standalone.

If your daughter is watching you take one of these, what your daughter is learning is the other half of this subject.

What to ask

• "Which product, exactly?" Not "a GLP-1." One formulation of one molecule is approved for her age.
• "Is a pediatric specialist involved?" A telehealth intake designed for adults is not that, and most of these programs will not treat a minor at all.
• "Has anyone screened for disordered eating?" The researchers who interviewed these families flagged it as a gap⁵.
• "What is the strength and nutrition plan alongside it?" Not an afterthought, given what adolescence is doing to bone and muscle at the same time⁶.
• "What is the plan for stopping?" Ask it at the start. It is the thing every family in that study was least certain about⁵.

Where this sits on the evidence scale

The approval is solid ground: a randomized, double-blind, placebo-controlled trial of 201 adolescents over 68 weeks, with an FDA-reviewed label built on it, is real evidence and more than most interventions offered to teenagers can claim. The effect was large and the dropout rate was no worse than placebo.

What is thin is everything past 68 weeks, everything about musculoskeletal development, and everything about the other three products — where the honest statement is not that they are unsafe for adolescents but that nobody has established anything either way. Unstudied rather than disproven is the distinction to carry into the appointment, because it is the difference between a question a specialist can weigh and an answer the research does not yet have.